摘要
为探讨美沙拉嗪联合思连康口服治疗溃疡性结肠炎的疗效及对炎症因子的影响,选取本院84例溃疡性结肠炎患者,采用数字表法随机分为联合组和对照组各42例。对照组采用美沙拉嗪口服治疗,联合组在对照组基础上联合思连康口服治疗,对比2组临床疗效、炎症因子水平、不良反应及复发情况。结果显示,联合组总有效率为95.24%,对照组总有效率为73.81%,2组比较差异有统计学意义(P<0.05)。治疗前,2组各项炎症因子水平对比差异无统计学意义(P>0.05);治疗后,2组炎症因子水平均低于治疗前,且联合组低于对照组(P<0.05)。联合组出现上腹不适1例,恶心1例,不良反应发生率为4.76%;对照组出现恶心1例,不良反应发生率为2.38%。2组比较差异无统计学意义(P>0.05)。随访6个月,联合组复发4例,复发率为9.52%;对照组复发13例,复发率为30.95%。2组比较差异有统计学意义(P<0.05)。结果表明,美沙拉嗪联合思连康治疗溃疡性结肠炎效果较好,能有效缓解机体炎症反应,且无严重不良反应,安全性较高,复发率低,值得推广应用。
This study was to investigate the effect of mesalazine plus siliankang(bifidobacterium tetravaccine tablet,BTT)on ulcerative colitis(UC),and their influence on body’s inflammatory factor(IF),enrolled84 UC patients from author’s hospital as research objects,and randomly divided them into control group(42 cases,orally administered mesalazine)and combination group(42 cases,mesalazine plus BTT);then,compared clinical effect,the level of inflammatory factors,and the status on unward reaction as well recurrence between the two groups.As results,in total effective rate combination group was significatnly higher than control group(95.24%vs 73.81%,P<0.05);in the level of IF,before treatment there was no statistical difference between the two groups(P>0.05),but after treatment both groups’levels of IF were declined,and combination group was more lower than control group(P<0.05);after treatment in combination group 1 cases suffered epigastric complain,1 case suffered nausea,thus untoward reaction incidence was up to 4.76%,meanwhile,in control group,1 cases suffered nausea,up to 2.38%,thus there was no statistical difference between the two groups(P>0.05);the 6 months of follow-up showed the recurrence rate of both groups had statistical difference[9.52%(4/42)vs 30.95%(13/42),P<0.05].Results show that mesalazine plus BTT has more better effect than alone mesalazine,and can effecitve relieve body’s inflammatory response without severe untoward reaction,as well as its safety is high,recurrence rate is also low.It is worthy of clinical popularization and application.
作者
石建强
SHI Jian-qiang(Linxia Prefecture's People's Hospital,Gansu 731100)
出处
《中国肛肠病杂志》
2019年第12期40-42,共3页
Chinese Journal of Coloproctology
关键词
溃疡性结肠炎
美沙拉嗪
思连康
疗效
炎症因子
Ulcerative colitis
Mesalazine
Siliankang
Effect
Inflammatory factor
